Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Next Previous
Search
Trial Profile

A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary) ; Cisplatin
  • Indications Stomatitis
  • Focus Therapeutic Use
  • Acronyms PREVLAR
  • Sponsors EpicentRx

    • Most Recent Events

    • 01 Jul 2023 Results assessing the safety and efficacy of RRx-001 in patients receiving head and neck chemoradiotherapy, published in the International Journal of Radiation Oncology, Biology, Physics.
    • 02 Jun 2023 Results presented in an EpicentRx Media Release.
    • 02 Jun 2023 According to an EpicentRx media release, based on results from this trial the U.S. Food and Drug Administration (FDA) granted Fast Track designation, which expedites the development and review process for RRx-001.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top